RichardC.FrankMD

Oncology • Norwalk, CT

Clinical Assistant Professor of Medicine.

Join to view full profile

Dr. Frank is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Frank's full profile

Already have an account?

Office
24 Stevens St
Norwalk, CT 06850
Phone+1 203-845-4811

Fax+1 203-845-4897
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1992 - 1996
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1989 - 1992
Stony Brook University Health Sciences Center School of MedicineClass of 1989

Certifications & Licensure

CT State Medical License 2000 - 2025
NY State Medical License 1990 - 2024
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Greenwich Magazine Castle Connolly, 2012-2014
Top Doctors: New York Metro Area Castle Connolly, 2011-2014
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Westport Magazine Castle Connolly, 2012
New Canaan-Darien Magazine Castle Connolly, 2012
Stamford Magazine Castle Connolly, 2012
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy Start of enrollment: 2001 Sep 01
Completed
Phase 2
Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Start of enrollment: 2005 Mar 01
Completed
Not Applicable
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Start of enrollment: 2006 Aug 01
Completed
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2006 Sep 15
Completed
Phase 2
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia Start of enrollment: 2008 Jan 15
Completed
Phase 2
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
Active, not recruiting
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Start of enrollment: 2010 Jun 01
Completed
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery Start of enrollment: 2012 Jun 12
Active, not recruiting
Phase 2, Phase 3
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL) Start of enrollment: 2013 Apr 23
Completed
Phase 2
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01
Completed
Phase 2
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
LGX818 for Patients With BRAFV600 Mutated Tumors Start of enrollment: 2014 Jan 14
Terminated
Phase 2
Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE) Start of enrollment: 2015 May 01
Completed
Phase 3
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer Start of enrollment: 2020 Jul 01
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

8 citations
Glycemic Control as an Early Prognostic Marker in Advanced Pancreatic Cancer.
Ipek Alpertunga, Rabail Sadiq, Deep Pandya, Tammy Lo, Maxim Dulgher, Sarah Evans, Bridget Bennett, Nancy Rennert, Richard C. Frank> ;Frontiers in Oncology. 2021 Feb 25
8 citations
Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibi...
Deep Pandya, Myra R Shah, Fuat Kaplan, Candice Martino, Gillian Levy, Mia Kazanjian, Stephen J. Batter, John A. Martignetti, Richard C. Frank> ;Cold Spring Harbor Molecular Case Studies. 2021 Feb 19
62 citations
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
W. Larry Gluck, Mrinal M. Gounder, Richard Frank, Ferry A.L.M. Eskens, Jean-Yves Blay, Philippe A. Cassier, Jean-Charles Soria, Sant P. Chawla, Vincent A. de Weger, An...> ;Investigational New Drugs. 2020 Jun 1
11 citations
ATM-Mutated Pancreatic Cancer: Clinical and Molecular Response to Gemcitabine/Nab-Paclitaxel After Genome-Based Therapy Resistance.
Candice Martino, Deep Pandya, Ronald Lee, Gillian Levy, Tammy Lo, Sandra Lobo, Richard C. Frank> ;Pancreas. 2020 Jan 1
5 citations
Subacute cutaneous lupus erythematosus induced by gemcitabine in 2 patients with pancreatic cancer
Matthew A. Cornacchia, Stephanie M. Gallitano, Richard C. Frank, Charles L. G. Halasz> ;JAAD Case Reports. 2019 Jun 26
42 citations
Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration
Julia A. Elvin, Rita Ort, Joseph Shuluk, Jennifer Long, Lauren Shelley, Ronald Lee, Zachary R. Chalmers, Garrett M. Frampton, Siraj M. Ali, Alexa B. Schrock, Vincent A...> ;The Oncologist. 2017 Apr 1
19 citations
90Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;European Journal of Cancer. 2015 Sep 1
129 citations
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
Peter M. Voorhees, Robert F. Manges, Pieter Sonneveld, Sundar Jagannath, George Somlo, Amrita Krishnan, Suzanne Lentzsch, Richard C. Frank, Sonja Zweegman, Pierre W. W...> ;British Journal of Haematology. 2013 May 1
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advance...
Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank R, Letrent SP, Ruiz-Garcia A, Taylor I, Liang JQ, Campbel...> ;J. Clin. Oncol.. 2012-09-20
Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in men with prostate cancer previously treated with taxane.
Petrylak DP, Kantoff PW, Mega AE, Dreicer R, Frank RC, Shore ND, Morris S, Olson WC, Israel RJ> ;J. Clin. Oncol.. 2012-02-10
The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer.
Shapiro GI, Frank R, Dandamudi UB, Hengelage T, Zhao L, Gazi L, Porro MG, Woo MM, Lewis LD> ;Cancer Chemother. Pharmacol.. 2012-02-01
Prostate-specific membrane antigen antibody-drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer.
Petrylak DP, Kantoff PW, Frank RC, Shore ND, Rotshteyn Y, Israel RJ, Olson WC, Ramakrishna T, Morris S> ;J. Clin. Oncol.. 2011-05-20
9 citations
Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report
Kabir Mody, Edward B. Strauss, Robert Lincer, Richard C. Frank> ;BMC Cancer. 2010 Oct 20
8 citations
The Hardest Job in Medicine
Richard C. Frank> ;Journal of Clinical Oncology. 2010 Jan 1
Influence of food on the pharmacokinetics (PK) of panobinostat (LBH589), an orally active histone deacetylase inhibitor, in patients with advanced cancer.
Lewis L, Frank R, Dandamudi UB, Gallagher J, Zhao L, Woo M, Hirawat S, Shapiro GI> ;J. Clin. Oncol.. 2009-05-20
Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): Preliminary safety and tolerability ...
Conte P, Campone M, Pronzato P, Amadori D, Frank R, Schuetz F, Rea D, Wardley A, Britten C, Elias A> ;J. Clin. Oncol.. 2009-05-20
165 citations
Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301
, , , , , , , , , , , , , , , > ;Journal of Clinical Oncology. 2009 Apr 10
4 citations
Response of carcinoma of unknown primary site affecting bone to thalidomide
Richard C. Frank, Fred Kaplan, Saraswathi Nair> ;The Lancet. Oncology. 2005 Jul 1
4 citations
Fetal microchimeric cells and breast cancer
Richard C. Frank> ;JAMA. 2004 Oct 6
20 citations
Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins
Anja Moldenhauer, Richard C. Frank, Javier Pinilla-Ibarz, Gudrun Holland, Piernicola Boccuni, David A. Scheinberg, Abdulgabar Salama, Karl Seeger, Malcolm A.S. Moore, ...> ;Journal of Leukocyte Biology. 2004 Sep 1
Low dose docetaxel, estramustine and thalidomide followed by maintenance thalidomide for the treatment of hormone refractory prostate cancer (HRPC): A phase II communi...
Frank RC, Coscia A, Versea L, Cohen N, Zelkowitz R, Ruskin A, Skeris A, Dodds P, Nair K> ;J. Clin. Oncol.. 2004-07-15
30 citations
Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements.
Gunnar Steineck, Victor E. Reuter, William Kevin Kelly, Richard C. Frank, Lawrence H. Schwartz, Howard I. Scher> ;Acta Oncologica. 2002 Jan 1
321 citations
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a pr...
Craig H. Moskowitz, Stephen D. Nimer, Andrew D. Zelenetz, Tania Trippett, Eric Hedrick, Daniel A. Filippa, Diane C. Louie, Maria Gonzales, Janine Walits, Nancy Coady-L...> ;Blood. 2001 Feb 1
74 citations
Inhibition of the Transforming Growth Factor β1 Signaling Pathway by the AML1/ETO Leukemia-associated Fusion Protein
Andrzej Jakubowiak, Celio Pouponnot, Francisco J. Berguido, Richard C. Frank, Shifeng Mao, Joan Massagué, Stephen D. Nimer> ;The Journal of Biological Chemistry. 2000 Dec 22
238 citations
Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients Wit...
Craig H. Moskowitz, Joseph R. Bertino, Jill R. Glassman, Eric Hedrick, Sonia Hunte, Nancy Coady-Lyons, David B. Agus, Andre Goy, Joseph G. Jurcic, Ariela Noy, James P....> ;Journal of Clinical Oncology. 1999 Dec 1
Join now to see all

Press Mentions

Danbury & Norwalk Hospitals in CT Serve as Trial Site for Lung Cancer & Colon Cancer Clinical TrialOctober 27th, 2020
Hospitals Offer New Clinical Trials for Cancer PatientsOctober 26th, 2020
NRG Oncology Approves Danbury and Norwalk Hospitals as Primary Sites for Clinical ResearchSeptember 22nd, 2019
Join now to see all